The Dayton Clinical Oncology Program (DCOP) was incorporated in the State of Ohio in 1982 as a non-profit 501 C-3 corporation. A Consortium Agreement was established between DCOP, the Dayton Area adult hospitals, and Wright State University (WSU). A governing board was established, and corporate bylaws were developed. Currently, DCOP has an elected Board of Directors with Howard M. Gross, M.D., DCOP Principal investigator, as Chairperson of the Board, Stuart Marl, M.D., Associate Principal Investigator, as Vice Chairperson, Sidney J. Pinkus, MBA, Chief Executive Officer of DCOP, as President of the Board, and 15 other Directors representing the 12 member hospitals, WSU, and at-large community members of our service area. The Board meets semi-annually to review budget reports and program activities. Since 1982, DCOP has successfully applied for and received funding from NCl as a CCOP. We are currently seeking continued funding through the five fiscal year period ending May 31, 2019 as an N-CORP. Our current staff includes 17 Oncology Research Nurses funded by our member hospitals, and 18 office staff funded by the grant, including directors for quality, regulatory, research projects, and education, regulatory coordinator, data coordinators, research coordinators, administrative assistant, and research associate. Our current active physician co-investigators total 78, representing our 12 hospitals and various specialties including oncology, radiation therapy, urology, surgery, gynecology, pulmonary and gastroenterology. WSU has been providing personnel, payroll, and accounting services support through a sub-contracting relationship established on December 23, 2001, when the grant was transferred from former fiscal agent Kettering Medical Center to DCOP. DCOP has continued as the grantee organization since that date.

Public Health Relevance

DCOP has been a vital part of the research community for 25 years as it has brought clinical trials to the Miami Valley Region of Ohio, Kentucky and Indiana. With funding as a new NCORP site, this consortium will continue to bring treatment and control trials the region, as well as cancer care delivery research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189957-05
Application #
9537421
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
St Germain, Diane
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dayton Clinical Oncology Program
Department
Type
DUNS #
613819200
City
Dayton
State
OH
Country
United States
Zip Code
45420
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 16 publications